AskVantage

Biotech and enhanced humans

New experimental chewing gum slows down the spread of COVID-19

Companies are coming up with all manner of ways to try and get life back to normal and one of the latest innovations is a new kind of chewing gum!

Key takeaways

  • To test the effectiveness of the chewing gum, the researchers took saliva samples from patients with COVID-19 and mixed these samples with a powdered form of the gum.
  • The researchers also demonstrated that the gum prevented a pseudotyped virus, a harmless virus with the Sars-CoV-2 spike protein on its surface, from infecting cells in the lab.
  • Second, although the gum significantly reduced infection of a virus that carried the Sars-CoV-2 spike, the researchers didn’t use the full Sars-CoV-2 virus in their experiments.
Cite or link to this article

Griffin, M. (2021) 'New experimental chewing gum slows down the spread of COVID-19', 311 Institute, 13 December. Available at: https://www.311institute.com/new-experimental-chewing-gum-slows-down-the-spread-of-covid-19/ (Accessed: 1 October 2026).

We’ve heard of COVID-19 vaccines come in aerosol form, plant form, and pill form, as well as ones that hack your DNA and now a new experimental chewing gum could reduce the spread of Sars-CoV-2, the virus that causes COVID-19, according to a recent study published in the journal Molecular Therapy. You might already have noticed headlines calling the findings “fresh hope” in our fight against COVID-19. But how excited should we be? And would this gum work against omicron, the newest variant of concern?

Evidence shows people infected with Sars-CoV-2 have high levels of virus in their saliva. So researchers in the US wanted to investigate whether a specially designed chewing gum could reduce the amount of virus in the mouth, and therefore potentially reduce its spread.

 Learn more about the Future of Healthcare, by Keynote Matthew Griffin

Chewing gum to promote oral health is not a new idea. Studies have shown that chewing gums containing certain substances such as calcium and bicarbonate can improve oral health, reducing the incidence of dental ailments and cutting the numbers of harmful bacteria. But specifically targeting a virus in this way is a novel approach.

Sars-CoV-2 gains entry into human cells by latching onto ACE2 proteins, which are found on the surfaces of certain cells in our body. The researchers produced a gum containing high levels of ACE2 proteins, produced in plants, with the idea being that the ACE2 proteins in the chewing gum could “trap” virus particles in the mouth, minimising the opportunity they have to infect our cells and spread to other people.

To test the effectiveness of the chewing gum, the researchers took saliva samples from patients with COVID-19 and mixed these samples with a powdered form of the gum. They found the treated saliva had significantly reduced numbers of Sars-CoV-2 virus particles compared to those treated with a placebo, the same gum but without the ACE2 protein.

The researchers also demonstrated that the gum prevented a pseudotyped virus, a harmless virus with the Sars-CoV-2 spike protein on its surface, from infecting cells in the lab. As little as 5mg of the gum was associated with significantly reduced viral entry into cells, while 50mg of the gum reduced viral entry by 95%. This suggests the ACE2 gum severely hinders the ability of the Sars-CoV-2 spike protein to infect cells.

Although these results seem promising, there are a number of reasons we can’t view this gum as a pandemic gamechanger just yet. First, this is early-stage research, meaning the experiments were conducted in a lab in controlled conditions rather than with real people.

The conditions in a lab experiment are going to be different to the conditions in a person’s mouth. While the researchers used a chewing simulator machine to show that the motion of chewing doesn’t affect the integrity of the ACE2 protein in the gum, there are other questions for which we don’t yet have answers.

For example, would the environment in a person’s mouth, such as body temperature and oral bacteria, impact the effectiveness of the gum? And how long would one piece of gum continue working for? It will be interesting to see whether the gum produces similar effects in people as it has in the lab if the research progresses to this stage.

Second, although the gum significantly reduced infection of a virus that carried the Sars-CoV-2 spike, the researchers didn’t use the full Sars-CoV-2 virus in their experiments. While the method they used, virus pseudotyping, is a tried and tested scientific method to assess virus entry into cells, it would be interesting to see how the gum affects the full Sars-CoV-2 virus.

As for whether the gum would be effective across different COVID variants, such as omicron, the principles of virology give us reason to be optimistic. Regardless of the variant and its mutations, Sars-CoV-2 gains entry into human cells by latching on to ACE2 proteins – which is key to how the gum works. That said, this is another question we won’t know the answer to for sure until the product is tested in real-world trials.

Finally, it’s important to understand what this gum is designed for. The researchers point out that its main use is likely to be reducing viral spread from people with COVID-19 to others, particularly in clinical settings. It’s unclear how well it would work as a prophylactic to prevent uninfected people getting the virus, particularly when Sars-CoV-2 can be transmitted through multiple routes including the eyes and nose as well as the mouth.

All the same, this gum could have exciting prospects in a clinical setting – for example reducing spread in dental surgeries or COVID hospital wards. When used in combination with current methods such as mask wearing, ventilation and vaccination, it could be another weapon in our arsenal for preventing the spread of COVID-19. But further research is needed before we can expect to be chewing it.

FAQ

Why does this matter?

Companies are coming up with all manner of ways to try and get life back to normal and one of the latest innovations is a new kind of chewing gum!

Matthew Griffin

About the author

Matthew Griffin Founder, 311 Institute

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath."

Read full bio

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath." 15-time best selling author of the "Codex of the Future" series, Matthew is the Founder and Futurist in Chief of the 311 Institute, a global Futures and Deep Futures advisory firm working with royal households, world leaders, G7, G20, and G77 governments, NGOs, and multi-national mid and mega cap firms to help them explore, shape, and lead the next 50 years of business and society.

An award-winning YouTube creator with over a million followers, with an unrivalled global reach and impact, Matthew is a highly sought-after international keynote speaker, lecturer, and mentor who collaborates with global leaders through the United Nations Alliance of Civilizations (UNAOC) and United Nations General Assembly (UNGA) to shape pivotal initiatives such as the UN’s AI for Humanity program, the United Nations Conference of the Parties (UN COP), and the World Economic Forum in Davos.

As the former Global Head of Cloud, National Security, and Enterprise Sales for companies including Atos, Dell-EMC, and IBM, Matthew has a proven track record of building multi-billion dollar business units and turning failing divisions into market leaders. His ability to identify, analyse, and communicate the implications of hundreds of emerging technologies and trends is unparalleled, and his insights are trusted by many of the world’s most respected organisations, including ABB, Accenture, Adidas, AON, ARM, BCG, Centrica, Citi, Coca-Cola, Dentons, Deloitte, Dow Jones, EY, Google, KPMG, Lego, Legal & General, LinkedIn, Microsoft, PepsiCo, Qualcomm, RWE, Samsung, Siemens AG and Siemens Energy, T-Mobile, UBS, VISA, Walmart, Workday, Worldpay and many others.

Regularly featured in the global media including the AP, BBC, Bloomberg, CNBC, Discovery, Forbes, Khaleej Times, Telegraph, TIME, ViacomCBS, WIRED, and the WSJ, Matthews mission is to help organisations create a fair and sustainable future whose benefits are shared by everyone irrespective of their ability, background, or circumstances.

What future do you need to see?

Choose one to get started on biotech and enhanced humans and the future of your organisation.

Where should Matthew reply?

Takes 30 seconds. No obligation. Matthew replies quickly. Privacy

Tag Cloud

Sources and further reading

  1. a recent study cell.com
  2. Chewing gum traps covid particles thesun.co.uk
  3. 28 11 2021 update on omicron who.int
  4. Omi.12289 onlinelibrary.wiley.com
  5. have shown pubmed.ncbi.nlm.nih.gov
  6. harmful bacteria pubmed.ncbi.nlm.nih.gov
  7. pseudotyped virus frontiersin.org
  8. through multiple routes ncbi.nlm.nih.gov

Source: first published by the 311 Institute on 13 December 2021. Cite as: Griffin, M. (2021). New experimental chewing gum slows down the spread of COVID-19. 311 Institute. https://www.311institute.com/new-experimental-chewing-gum-slows-down-the-spread-of-covid-19/

You are welcome to quote this article with credit and a link to the original.

Book a Keynote